Kirkland & Ellis International LLP advised Synteract, Inc., a portfolio company of Gryphon Investors, on the acquisition of Harrison Clinical Research Group, a Munich-based, full-service clinical research organization with 15 offices in 15 countries and approximately 500 employees. The transaction is expected to close early in the first quarter of 2013. The value of the transaction is confidential. Kirkland advises Synteract and Gryphon on an ongoing basis.
The Kirkland team was led by Munich corporate/private equity partners Erik Dahl, Dr. Christian Zuleger and Dr. Jan Schinköth, with tax partner Dr. Roderic Pagel (Munich), corporate partners Noah Boyens (San Francisco) and Nicole Schlatter (Munich), finance partners Christopher Kirkham (San Francisco) and Brian Ford (Los Angeles) and corporate/private equity associates Dr. Kai Terstiege, Dirk Kramer, Dr. Philipp Mangini-Guidano (Munich) and Ben Beerle (San Francisco).